# Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

Study · id `cardio:ct-nct02849080` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02849080](<https://clinicaltrials.gov/study/NCT02849080>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02849080

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 504 participants.

## Technical summary

Registry record NCT02849080. Randomized; no masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2018-02-28 (actual). Results posted on 2020-02-17.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 504 participants (enrolled count; ClinicalTrials.gov record NCT02849080, source copy `cardio:ctgov-nct02849080-2022-07-20`, retrieved 2026-10-26)
- Started: 2016-09-20 (actual) (ClinicalTrials.gov record NCT02849080, source copy `cardio:ctgov-nct02849080-2022-07-20`, retrieved 2026-10-26)
- Primary completion: 2018-02-28 (actual) (ClinicalTrials.gov record NCT02849080, source copy `cardio:ctgov-nct02849080-2022-07-20`, retrieved 2026-10-26)
- Completion: 2019-03-27 (actual) (ClinicalTrials.gov record NCT02849080, source copy `cardio:ctgov-nct02849080-2022-07-20`, retrieved 2026-10-26)
- Results first posted: 2020-02-17 (ClinicalTrials.gov record NCT02849080, source copy `cardio:ctgov-nct02849080-2022-07-20`, retrieved 2026-10-26)
- Countries: United States; Argentina; Austria; Belgium; Brazil; Egypt; Norway; South Korea; Switzerland; Türkiye (ClinicalTrials.gov record NCT02849080, source copy `cardio:ctgov-nct02849080-2022-07-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02849080-2022-07-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
- Acronym: PIONEER 7
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): semaglutide
- Intervention (Drug): sitagliptin
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial (`cardio:pubmed-31189520`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial (`cardio:pubmed-33318068`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3d855b530c59917bb9c8a0dfe74dec3b58a97b0b1ef57e14b4fa933dc322c20a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
